Intriguingly, we also showed that, in an in vivo mouse model, platinum chemotherapeutic agents preferentially kill EpCAM-negative cancer cells in comparison with EpCAM-positive cancer cells, suggesting that the remaining subpopulation of EpCAM-positive cancer cells is inherently responsible for tumor recurrence after such treatment of chemotherapy. Here, EPCAM is linked to cancer.